This moment represents a shift in obesity care, moving from injectable-centric to patient-friendly formats
Among participants, background use of GLP-1RA and SGLT2i was 5.8% and 8.9%, respectively, and treatment effect of finerenone on cardiovascular death was consistent regardless of those medication usages
No wonder they ate less, but evidently the degree of gastrointestinal discomfort did not correlate with how much less they ate
\Safety Profile: Mild, transient side effects
Patients should be aware of symptoms suggesting gallbladder disease, including right upper quadrant abdominal pain, particularly after fatty meals, and should seek medical evaluation if such symptoms occur
Do they occur after meals or at night